ADMA Biologics

ADMA Biologics (NASDAQ: ADMA) is a Ramsey, New Jersey-based biopharmaceutical company that develops, manufactures and commercializes specialty plasma-derived biologics for immune-compromised patients and for the prevention and treatment of infectious diseases. It is one of a small number of vertically integrated plasma-products manufacturers based in the United States: it operates a cGMP fractionation and purification plant in Boca Raton, Florida with capacity for roughly 600,000 litres of plasma per year, seven company-owned plasma collection centres, and supply relationships with more than 260 third-party collection centres. The commercial portfolio is three FDA-approved products — ASCENIV (immune globulin intravenous, human–slra), BIVIGAM (immune globulin intravenous, human) and Nabi-HB (hepatitis B immune globulin, human) — sold to hospitals, specialty pharmacies and distributors. The company has been consistently profitable since 2024 and funds a share repurchase programme from operating cash flow while investing in manufacturing yield improvements and earlier-stage pipeline work.